文献速递白血病

维奈克拉联合低甲基化剂治疗新诊断急性髓系白血病:301例连续患者中应答与生存的基因型特征

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
PubMed 文献 · Am J Hematol · 2023-12-10

这项回顾性研究纳入301例新诊断急性髓系白血病成人患者(中位年龄73岁,62%为原发),分析维奈克拉联合低甲基化剂治疗的分子预测因素与生存。完全缓解(含血细胞计数恢复或不恢复)182例(60%)。NPM1、IDH2、DDX41突变与较高完全缓解率相关,TP53、FLT3-ITD、RUNX1突变与较低完全缓解率相关。基于完全缓解与基因特征构建的三层生存模型优于ELN遗传风险模型。

要点

  • NPM1(86% vs 56%)、IDH2(80% vs 58%)、DDX41(100% vs 58%)突变者完全缓解率较高
  • TP53(40% vs 67%)、FLT3-ITD(36% vs 63%)、RUNX1(44% vs 64%)突变者完全缓解率较低
  • 基于完全缓解与基因特征的三层生存模型优于ELN遗传风险模型(AIC 1661 vs 1750)

核心结论

  • 本研究识别了预测维奈克拉联合低甲基化剂治疗新诊断急性髓系白血病应答的基因型特征,并提出基于完全缓解且整合遗传学的三层生存模型。

研究设计与样本

  • 回顾性研究纳入301例接受维奈克拉联合低甲基化剂一线治疗的成人新诊断急性髓系白血病患者,中位年龄73岁,62%为原发。
  • ELN遗传风险分布为预后良好15%、中等16%、不良69%。

主要发现

  • 完全缓解(含血细胞计数恢复或不恢复)见于182例(60%)患者。
  • 多因素分析中,完全缓解的有利预测因素为NPM1(86% vs 56%)、IDH2(80% vs 58%)、DDX41(100% vs 58%)突变,不利因素为TP53(40% vs 67%)、FLT3-ITD(36% vs 63%)、RUNX1(44% vs 64%)突变,校正年龄、核型和治疗相关资质后各突变仍显著。
  • 完全缓解率从仅存在不利突变且无有利突变者的36%至仅存在有利突变且无不利突变者的91%。
  • 中位随访8.5个月,记录174例死亡和41例异基因干细胞移植。
  • 多因素分析中,生存不良风险因素包括未达完全缓解(HR 3.4,95% CI 2.5-4.8)、不良核型(HR 1.6,95% CI 1.1-2.6)、TP53突变(HR 1.6,95% CI 1.0-2.4)和IDH2突变缺失(HR 2.2,95% CI 1.0-4.7)。

关键数值与推荐

  • 完全缓解的有利突变:NPM1(86% vs 56%)、IDH2(80% vs 58%)、DDX41(100% vs 58%)。
  • 完全缓解的不利突变:TP53(40% vs 67%)、FLT3-ITD(36% vs 63%)、RUNX1(44% vs 64%)。
  • 完全缓解率范围:仅不利突变且无有利突变者36%,仅有利突变且无不利突变者91%。
  • 生存不良风险因素:未达完全缓解(HR 3.4,95% CI 2.5-4.8)、不良核型(HR 1.6,95% CI 1.1-2.6)、TP53突变(HR 1.6,95% CI 1.0-2.4)、IDH2突变缺失(HR 2.2,95% CI 1.0-4.7)。
  • 风险模型分层:低危(n=130;中位生存28.9个月)、中危(n=105;中位9.6个月)、高危(n=66;中位3.1个月;p<.001)。

临床怎么用

  • 作者提出基于完全缓解且整合遗传学的三层生存模型,用于接受维奈克拉联合低甲基化剂一线治疗的新诊断急性髓系白血病患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venetoclax + hypomethylating agent (Ven-HMA) is currently the standard frontline therapy for older/unfit patients with newly diagnosed acute myeloid leukemia (ND-AML). Our objective in the current retrospective study of 301 adult patients (median age 73 years; 62% de novo) with ND-AML was to identify molecular predictors of treatment response to Ven-HMA and survival; European LeukemiaNet (ELN) genetic risk assignment was favorable 15%, intermediate 16%, and adverse 69%. Complete remission, with (CR) or without (CRi), count recovery, was documented in 182 (60%) patients. In multivariable analysis, inclusive of mutations only, "favorable" predictors of CR/CRi were NPM1 (86% vs. 56%), IDH2 (80% vs. 58%), and DDX41 (100% vs. 58%) and "unfavorable" TP53 (40% vs. 67%), FLT3-ITD (36% vs. 63%), and RUNX1 (44% vs. 64%) mutations; significance was sustained for each mutation after adjustment for age, karyotype, and therapy-related qualification. CR/CRi rates ranged from 36%, in the presence of unfavorable and absence of favorable mutation, to 91%, in the presence of favorable and absence of unfavorable mutation. At median follow-up of 8.5 months, 174 deaths and 41 allogeneic stem cell transplants (ASCT) were recorded. In multivariable analysis, risk factors for inferior survival included failure to achieve CR/CRi (HR 3.4, 95% CI 2.5-4.8), adverse karyotype (1.6, 1.1-2.6), TP53 mutation (1.6, 1.0-2.4), and absence of IDH2 mutation (2.2, 1.0-4.7); these risk factors were subsequently applied to construct an HR-weighted risk model that performed better than the ELN genetic risk model (AIC 1661 vs. 1750): low (n = 130; median survival 28.9 months), intermediate (n = 105; median 9.6 months), and high (n = 66; median 3.1 months; p < .001); survival in each risk category was significantly upgraded by ASCT. The current study identifies genotype signatures for predicting response and proposes a 3-tiered, CR/CRi-based, and genetics-enhanced survival model for AML patients receiving upfront therapy with Ven-HMA.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Gangat N, Karrar O, Iftikhar M, et al. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2023. PMID: 38071734. doi:10.1002/ajh.27138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。